GlycanDx-MODY - a glycomics precision diagnostic assay for MODY diabetes

GlycanDx-MODY是一种用于识别HNF 1A型青年成熟型糖尿病（MODY）患者的检测。这是一种影响高达4%的糖尿病患者（英国有40 K-160 K例）的糖尿病，可以用廉价的口服药物治疗。大多数MODY患者被误诊并被处方胰岛素，这并不能治疗他们的疾病，既不方便又昂贵。从长远来看，患者患失明、肾脏疾病和心脏病的风险更高。有可用的基因测试，但它们没有被全科医生广泛使用，因为它们太昂贵，结果很难解释。这是一个由Ludger领导的合作项目，Ludger是一家总部位于牛津的生物科学公司，沿着还有非资助的合作伙伴Genos（欧洲SME）和OCDEM（牛津糖尿病研究小组）。在一项针对200名糖尿病患者的研究中，该测试阳性识别出HNF 1A-MODY患者。该测试是负担得起的（基因测试价格的四分之一），快速（~ 3天周转），结果很容易解释。我们希望进一步开发该检测方法，作为诊断或筛查工具用于常规临床用途。该可行性研究旨在规划该测试的下一个开发和商业化阶段，这将为有效推进该项目以造福患者提供蓝图。

GlycanDx-MODY is a test to identify patients with HNF1A-type Maturity Onset Diabetes of the Young (MODY). This is a type of diabetes affecting up to 4% of diabetics (40K-160K cases in the UK) that can be treated with inexpensive oral drugs. Most MODY patients are misdiagnosed and prescribed insulin, which does not treat their disease, is inconvenient and expensive. In the long term, patients have a higher risk of blindness, kidney disease and heart disease. There are genetic tests available, but they are not widely used by GPs because they are too expensive and the results are difficult to interpret. This is a collaborative project led by Ludger, an Oxford based bioscience company, along with non-funded partners Genos (European SME) and OCDEM (Oxford diabetes research group). In a study of 200 diabetes patients the test positively identified those with HNF1A-MODY. The test is affordable (quarter of the price of genetic tests), quick (~ 3 days turnaround) and the results are easy to interpret. We would like to further develop this assay for routine clinical use as a diagnostic or screening tool. This Feasiblity Study is to plan the next stage in development and commercialisation of the test which will result in a blueprint to progress the project efficiently for the benefit of patients.